C. Kaderbhai

发表

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Laurence Zitvogel, Matthew D. Hellmann, Nicolas Pons, 2018, Science.

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life

R. Boidot, C. Kaderbhai, Julie Niogret, 2022, Frontiers in Oncology.

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes

N. Girard, D. Planchard, P. Dubray-Longeras, 2021, Targeted Oncology.

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

R. Boidot, F. Ghiringhelli, S. Ladoire, 2022, Breast Cancer Research.

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study

C. Coutant, A. Bertaut, Jean-David Fumet, 2021, European Journal of Cancer.

Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma

R. Boidot, A. Bertaut, J. Vincent, 2017, Oncoimmunology.

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

R. Boidot, F. Ghiringhelli, S. Ladoire, 2022, npj Breast Cancer.

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer

F. Ghiringhelli, C. Kaderbhai, C. Truntzer, 2021, Cancers.

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

B. Chauffert, R. Boidot, A. Bertaut, 2016, Oncotarget.

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

R. Boidot, P. Saintigny, Jean-David Fumet, 2017, Oncoimmunology.

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer

R. Boidot, F. Ghiringhelli, S. Ladoire, 2023, Cancers.

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer

Laurent Arnould, R. Boidot, F. Ghiringhelli, 2016, Oncotarget.

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer

R. Boidot, F. Ghiringhelli, B. Routy, 2022, Journal for ImmunoTherapy of Cancer.

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

R. Boidot, F. Ghiringhelli, L. Arnould, 2021, Lung cancer.

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study

C. Coutant, A. Bertaut, Jean-David Fumet, 2022, European Journal of Cancer.

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report

F. Ghiringhelli, C. Kaderbhai, S. Zanetta, 2022, The American journal of case reports.

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type

R. Boidot, F. Ghiringhelli, S. Chevrier, 2023, International journal of molecular sciences.

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Jean-David Fumet, F. Ghiringhelli, S. Ladoire, 2022, Cancer Research.

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

R. Boidot, Jean-David Fumet, F. Ghiringhelli, 2017, Anticancer research.

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort

R. Boidot, A. Bertaut, F. Ghiringhelli, 2021, Journal of thoracic disease.

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results

A. Bertaut, S. Ladoire, C. Kaderbhai, 2023, Breast.

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

R. Boidot, Stefano Kim, L. Arnould, 2023, Molecular Cancer.

Smartphone-based application and nurses' interventions for symptoms monitoring in patients treated with oral anticancer agents: A 1-year follow-up in a tertiary cancer center.

C. Kaderbhai, J. Blanc, Antonin Schmitt, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

M. Mouret-Reynier, C. Kaderbhai, C. Jouannaud, 2024, European journal of cancer.

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

C. Coutant, A. Bertaut, S. Ladoire, 2023, Breast Cancer.

Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience

S. Ladoire, C. Kaderbhai, I. Desmoulins, 2024, Cancers.